efavirenz tablet film coated

1 INDICATIONS & USAGE Efavirenz tablets in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. Efavirenz is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. (1)

camber pharmaceuticals, inc.

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] adverse drug reaction` `[3] off label use` `[4] nausea` `[5] fatigue` `[6] headache` `[7] rash` `[8] diarrhoea` `[9] dyspnoea` `[10] drug hypersensitivity`

4 years ago

OVAL YELLOW H 4

16 HOW SUPPLIED/STORAGE AND HANDLING 16.2 Tablets

EFAVIRENZ tablets, USP are available as follows: Tablets 600 mg are yellow, capsular-shaped, film-coated tablets debossed with ‘H’ on one side and ‘4’ on the other side. Bottles of 30 NDC 31722-504-30 Bottles of 250 NDC 31722-504-25 16.3 Storage

EFAVIRENZ tablets, USP should be stored at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

More pills like OVAL H 4

Related Pills

Sulfamethoxazole and Trimethoprim Sulfamethoxazole 800 MG Trimethoprim 160 MG Oral Tablet

AvPAK

Sulfamethoxazole and Trimethoprim Sulfamethoxazole 800 MG Trimethoprim 160 MG Oral Tablet

AvPAK

hydralazine hydrochloride tablet

camber pharmaceuticals

hydralazine hydrochloride tablet

camber pharmaceuticals

sulfamethoxazole and trimethoprim tablet

avpak

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site